Endocrinology Department, 'Groupement Hospitalier Est' Hospices Civils de Lyon, Lyon, France.
Lyon 1 University, Lyon, France.
Eur J Endocrinol. 2019 Jul 1;181(1):K1-K9. doi: 10.1530/EJE-18-1014.
Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease, but its effectiveness in Cushing's syndrome of ectopic or occult origin remains to be investigated.
In this case series, cabergoline was used in combination with steroidogenesis inhibitors in nine patients with severe Cushing's syndrome of ectopic or occult origin. Cabergoline's effectiveness enabled rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism in three of the cases.
In the literature, we found only 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, alone or in combination. Yet of these 11 cases, 10 responded.
Although limited, the existing experience highlights the potential value of cabergoline in the treatment of ectopic or occult Cushing's syndrome.
卡麦角林已被证明对治疗中度库欣病有一定疗效,但它在异位或隐匿性起源的库欣综合征中的疗效仍有待研究。
在本病例系列中,卡麦角林与类固醇生成抑制剂联合用于 9 例异位或隐匿性起源的严重库欣综合征患者。卡麦角林的疗效使类固醇生成抑制剂能够迅速停药,并使其中 3 例长期控制高皮质醇血症。
在文献中,我们仅发现 11 例异位或隐匿性库欣综合征患者单独或联合使用多巴胺受体激动剂治疗的病例。然而,在这 11 例患者中,有 10 例得到了缓解。
尽管经验有限,但现有经验强调了卡麦角林在治疗异位或隐匿性库欣综合征中的潜在价值。